Back to 
Quadrature Capital Ltd
Quadrature Capital Ltd
ENGN
3 quarters
Position history for Quadrature Capital Ltd's holdings in enGene Therapeutics Inc.
Yes. Quadrature Capital holds 239,035 shares of ENGN (enGene Therapeutics), worth $413,531, as of its Q2 2026 13F filing. It increased the position from 33,797 shares in Q1 2026. Quadrature Capital has held ENGN since Q4 2025, across 3 quarterly 13F filings.
Current Value
$413,531
Current Shares
239,035
Total Value Change
-$25,173
Total Shares Change
+190,452
Quarter-by-Quarter History
Other major holders of ENGN: Adage Capital Partners GP, L.L.C., Janus Henderson Group Ltd.